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Medical Centre, Rotterdam, and 3Surgery, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital,
Plesmanlaan 121, NL-1066 CX Amsterdam, The NetherlandsObjective. To quantify the costs of treatment in critical limb ischaemia (CLI) and to compare costs and effectiveness of two
treatment strategies: spinal cord stimulation (SCS) and best medical treatment.
Methods. One hundred and twenty patients with CLI not suitable for vascular reconstruction were randomised to either
SCS in addition to best medical treatment or best medical treatment alone. Primary outcomes were mortality, amputation
and cost. Cost analysis was based on resources used by patients for 2 years after randomisation. Both medical and non-
medical costs were included.
Results. Patient and limb survival were similar in the two treatment groups. Costs of in-hospital-stay and institutional
rehabilitation constituted the predominant part (G70%) of the total costs of medical care in CLI. Cost of SCS-implantation
and complications (V7950 per patient) exceeded by far cost due to amputation procedures (V410 per patient). The total costs
of treatment were V36,600 per patient over 2 years for the SCS-group vs. V28,700 for best medical treatment alone (28%
higher for SCS-group, pZ0.009).
Conclusions. Total costs of treatment in CLI are high. Major components are hospital and rehabilitation costs. In contrast to
recent reviews, there were no long-term benefits of SCS-treatment. Therefore, cost-effectiveness is reduced to cost-
minimisation and SCS-treatment is considerably more expensive than best medical treatment.Keywords: Cost analysis; Cost-effectiveness; Critical limb ischaemia; Spinal cord stimulation; Electrical stimulation; Meta-
analysis; Peripheral vascular disease; Prognosis; Risk factors; Survival; Trials.Background
Critical limb ischaemia (CLI) threatens the survival of
an extremity and often causes lifelong disablement
from a painful leg. Lower-extremity amputation bears
a high risk of disability, prolonged institutionalisation
or death.1–4 Compared with amputation, revascular-
isation is associated with better perioperative morbid-
ity and mortality. Limb preservation should be the
goal, yet many patients with critical leg ischaemia are
poor candidates for the preferred therapeutic options
of percutaneous transluminal angioplasty or surgical
revascularisation.
Many authors have recommended the use of
spinal cord stimulation (SCS) in patients with limb-ing author. H.M. Klomp, MD, HOD, Department of
herlands Cancer Institute Antoni van Leeuwenhoek
lesmanlaan 121, NL-1066 CX Amsterdam, The
: h.klomp@nki.nl
0500 + 09 $35.00/0 q 2005 Elsevier Ltd. All rights reserthreatening ischaemia in whom vascular reconstruc-
tion is not an option.5–19 SCS involves implantation
of a pacemaker with epidural lead activating the
dorsal columns of the spinal cord. Dorsal column
stimulation at Th10-L1 level induces paraesthesia in
the lower extremities, thereby alleviating ischaemic
pain. Pain relief has been reported as excellent in
CLI and limb survival far better than expected (68–
80% after 1 year).6,8,12,20,21 In a multicentre random-
ised trial,22 we found that SCS-treatment was no
more effective than best medical treatment alone in
preventing amputations. Recently, however, several
reviews concluded that SCS is beneficial (in selected
patients).18,19,23 Since these reviews contain major
weaknesses and the available information on
costs in CLI involved is very limited,24–26 we
present a reconsideration of the evidence together
with a detailed analysis of costs.
If costs were considered in CLI, often these were
‘roughly’ calculated using charges/fees and with littleEur J Vasc Endovasc Surg 31, 500–508 (2006)
doi:10.1016/j.ejvs.2005.11.013, available online at http://www.sciencedirect.com onved.
Cost-effectiveness of SCS in Critical Limb Ischaemia 501information about the differentiation of the costs. This
may result in bias.
We aimed to study the total direct and indirect
medical costs of critical limb ischaemia within the
framework of a randomised trial. We present estimates
of the full cost price, based on real resource use, in
substantial patient groups.MethodsStudy design
The trial design has been published.22,27 In brief,
patients with CLI as characterized by persisting rest
pain or ischaemic skin lesions1 were eligible, if
vascular reconstruction was not possible. From 17
hospitals in The Netherlands, 120 patients were
enrolled from 1991 until 1996. The ethical committees
at each participating centre approved the study
protocol, and patients gave written informed consent.
The treatment strategies SCS in addition to best
medical treatment (‘SCS-treatment’) and best medical
treatment alone (‘standard treatment’) were allocated
at random to eligible patients using balanced block
randomisation.Treatment
Standard treatment included analgesics, antithrombo-
tic and haemorrheologic drugs, local wound care and
antibiotics, if indicated. There was a list of rec-
ommended medication, but no fixed treatment regi-
men. Those patients allocated to SCS treatment
additionally received an implantable spinal cord
stimulation system. A quadripolar lead (Medtronic)
was placed in the epidural space and connected to an
Itrell II pulse generator (Medtronic). Both treatment
regimens initially aimed at adequate pain suppres-
sion. During follow-up, the treatment effect was
optimised by altering medication, stimulation settings
or both. Patients receiving SCS-treatment were
checked regularly by a neurosurgeon or
anaesthesiologist.
All patients were assessed before randomisation, at
1, 3, 6, 12, 18 months after randomisation, and at the
end of the study. After each follow-up visit, patients
completed a questionnaire on consumption of health
resources. Between follow-up visits patients came to
the hospital as often as necessary. The primary
outcome measure was limb survival, defined as
absence of ‘major’ amputation (on level of foot or
higher).28Background of the cost analysis
The viewpoint of the cost analysis was societal, thus all
costs and consequences were taken into account. Cost
analysis was based on recorded resource use by
patients for 2 years after randomisation or until
death, if this occurred within 2 years. The costs were
calculated per patient as the product of volumes and
market prices. Volumes of the cost items were
collected for all patients. Market prices were estimated
in smaller samples. All costs were converted to 1993
Euros (DFL 100ZV4538), according to the calculation
factor of the The Nederlandsche Bank (www.dnb.nl).
Costs were not discounted given the short time
perspective (2 years per patient). In the successive
time periods (0–1, 1–3, 3–6 months after randomis-
ation, etc.) volumes of resource use per patient were
calculated from the observed volumes divided by the
number of patients at risk. This method was an
adaptation of the product-limit method as used in
survival analysis.29Use of resources
Costs were classified into direct medical costs (inside
and outside the hospital), direct non-medical costs and
indirect costs.30 The components of the medical costs
in CLI are summarized in Table 2. Direct non-medical
costs consisted of travel expenses and out-of-pocket
expenses on home adaptations (e.g. removal of
thresholds for wheelchairs, bathroom adaptations).
Indirect non-medical costs involved non-professional
help to patients externally to the health sector (e.g.
transportation by relatives and friends or domestic
help). We did not include costs caused by loss of
production due to absence from work, since the
majority of patients were retired from work.
Hospital admissions were classified as directly
related to CLI (wound care, amputations, compli-
cations), related to CLI (other vascular events,
including cardio- and cerebrovascular events) or not
related to CLI. In The Netherlands, nursing homes
have adequate facilities for rehabilitation; therefore,
temporary stay in nursing homes is common for
elderly amputees. As for homes for the elderly, only
new admissions (after randomisation) were taken into
account.
Volume information on outpatient visits, direct
medical cost items outside the hospital and non-
medical care was primarily collected from patient
questionnaires. Data on operative procedures, in-
hospital stay and rehabilitation, and medication
usage were available from the case-record-forms filledEur J Vasc Endovasc Surg Vol 31, May 2006
H. M. Klomp et al.502in by the surgeons. Furthermore, information was
checked in hospital administrations and hospital
information systems.Table 1. Baseline characteristics of the SCS and standard treatment
groups
Characteristics SCS (nZ60) Standard (nZ60)
Male/female 33/27 (55/45%) 37/23 (62/38%)
Age [year] 73.1G9.8 72.1G10.6
Diabetes 22 (37%) 23 (38%)
‘Other leg’
Symptomatic 19 (32%) 29 (48%)
Amputated 9 (15%) 7 (12%)
Smoking
QuittedO1 year 22 (37%) 16 (27%)
Still smoking 18 (30%) 26 (44%)Costing resources
For evaluation of the costs, we first identified the
fundamental cost items. A detailed cost analysis was
performed to estimate market prices for the important
determinants, i.e. those with large volumes or high
prices. These were primarily direct medical costs, such
as in-hospital-stay, operative procedures, and admis-
sion to nursing home or rehabilitation clinic. For minor
cost items, as travel expenses and out-of-pocket
payments, charges or expert estimates were used as
approximations of the market prices.
Hospital admission prices were assessed in detail,
using cost registrations to quantify attendance by
health professionals, supplies, equipment, and capital
costs (fixed annual costs of running the unit). We
estimated prices of lower limb amputations by
recording the presence and time of various health
professionals during amputation procedures. Regis-
trations were performed in one university hospital and
two general hospitals. Prices of supplies, equipment,
and capital costs were obtained from a detailed
department based cost registration. These data were
available from the hospital information system. The
price of implantation of the SCS device was estimated
using presence of personnel and time registrations
during 20 consecutive implantation procedures; yet
the main costs of SCS-implantation arose from the
price of the Itrell II pulse generator and Quad lead
(V7200). The prices of outpatient visits were based on
department based cost registrations. Prices of admis-
sion to a nursing home or rehabilitation clinic were
available from other Dutch national investigations.31,32
Prices for rehabilitation were adjusted according to
expert opinion on the amount of medical care
consumed by vascular amputees in relation to the
average patient in a rehabilitation clinic.CVA or TIA 13 (22%) 16 (27%)
Myocardial infarction 23 (38%) 22 (37%)
Angina pectoris 12 (20%) 15 (25%)
Rest pain only 22 (37%) 19 (32%)
Ischaemic skin lesions 38 (63%) 41 (68%)
Gangrene 24 (40%) 23 (38%)
Vasc. reconstructions
Nil 11 (18%) 15 (25%)
1 or 2 25 (42%) 29 (48%)
O3 19 (32%) 20 (33%)
Sympathectomy 21 (35%) 19 (32%)
Ankle systolic pressure
[mmHg]
35.2G25 41.6G22
Ankle-to-brachial
pressure index
0.23G0.16 0.28G0.13
Data are number (%) or meanGSD.Statistical analysis
All data were recorded on standardized forms and
entered in a concurrent database. Analysis of both
clinical outcome and cost was by ‘intention to treat’
and included all randomised patients. Patient and
limb survival were estimated and compared with
Kaplan–Meier analysis and log-rank tests. In the
analysis of limb survival, patients were censored at
death. Cost differences between groups were analysed
by Mann–Whitney test. For all hypothesis tests,Eur J Vasc Endovasc Surg Vol 31, May 2006p-values are stated, with p!0.05 interpreted as
statistically significant.Results
Sixty patients were randomly assigned to receive SCS-
treatment and 60 to receive standard treatment. Mean
duration of hospitalisation for SCS-implantation was
4.9 (G2.3) days. In two patients, adequate implan-
tation proved to be impossible, and one patient
refused implantation. The two treatment groups
were comparable in terms of demographic and clinical
characteristics. Mean age was 72.6 (range 38–89) years,
58% were males, 38% had diabetes, and 68% were
(former) smokers (Table 1). Median follow-up was 2
years (range 8–59 months).
There was no significant difference in patient and
limb survival between the two treatment groups
(Fig. 1). Cumulative patient survival at 2 years was
64% in the SCS-group vs. 63% in the standard group
(HRZ1.09, pZ0.96). Limb survival at 2 years was 52
and 46%, respectively (HRZ0.82, pZ0.47). Analysis of
amputation levels revealed no significant differences.
In the SCS-group, 18 complications (lead displace-
ments or inadequate stimulation) were treated by
operative repositioning procedures.
In Table 2, the unit costs for applicable cost items are
summarized, with separate information for university
Fig. 1. Mortality and amputation in CLI. The upper curves
indicate patient survival for both treatment groups (‘SCS’
and ‘standard’ treatment); the lower curves indicate
amputation free survival. The area between the upper and
lower curves represents the proportion of patients alive with
major amputation. Patients at risk: at 12 months 47/44, at 24
months 21/19.
Cost-effectiveness of SCS in Critical Limb Ischaemia 503and general hospitals. Table 3 shows how long the
patients spent in hospital, rehabilitation centre and
nursing home in both treatment groups. Most in-
hospital days (over 80%) were directly related to CLI.
Only four intensive care unit days were noted (in the
standard group). Although in the SCS-group patients
spent less days in rehabilitation clinics, there were
more admissions to nursing homes. Consequently, the
costs of rehabilitation (in clinics and nursing homes
together) were similar (V6760 vs. 7480 at 2 years).
Costs of in-hospital-stay and institutional rehabilita-
tion constituted the predominant part of the total costs
of medical care in CLI. Table 4 shows mean cumulative
costs per patient according to cost type for both
treatments.
Obviously, cost for operative procedures was
much higher in the SCS-group because of implan-
tation of the SCS-device (V7770). In the first month
after randomisation more in-hospital days in the
SCS-group occurred, due to hospitalisation for the
implantation procedure. Over a 2-year period, cost of
SCS-implantation and complications (V7950 per
patient) far exceeded the cost due to amputation
procedures (V410 per patient). Outpatient cost was
higher for SCS-treatment, because of checkups by the
neurosurgeon or anaesthesiologist. In the SCS-group
more patients moved to homes for the elderly, while
in the standard group more patients received
professional care in their own home. Again, com-
bined societal costs for homes for the elderly and
domestic professional care were comparable in SCS-
and standard group (V6120 vs. V5040). For both
medication and medical supplies, costs were lower in
the SCS group by about 30%. Direct and indirect non-
medical costs had little impact, but were somewhathigher for SCS-treatment. Fig. 2 shows the total cost
and its components over 2 years. After 2 years of
treatment, costs of SCS-treatment per patient were
V7900 (28%) higher as compared to standard
treatment (V36,600 vs. 28,700, pZ0.009).
Since, mortality was high (23% of the patients died
within 1 year, 36% within 2 years), a considerable
proportion of patients did not contribute to the cost
increase during the entire time period of 2 years.
Adjusted for mortality, mean costs per patient were
V31,400 for the SCS group and V23,800 for the
standard group, thus 32% higher for SCS-treatment
(pZ0.002).Discussion
Over 2 years, the costs of SCS-treatment were about
V7900 (28%) higher as compared to best medical
treatment alone. Initial costs in SCS-treatment were
high due to device implantation. Since all other costs
evolved similarly in both treatment groups, SCS-
treatment remained the more expensive therapy
during follow-up. Survival and amputation-free
survival were similar in the two treatment groups
of patients with CLI; therefore, cost-effectiveness is
reduced to cost-minimisation analysis. Based on limb
survival (HRZ0.82), the ‘number needed to treat’
(NNT) to save one limb was estimated at 14,
resulting in V110,000 per limb saved. Using for
example a health value (utility) for below-knee
amputation of 0.61,33 this would correspond to at
least V280,000 per QALY gained. Hence, from a
societal perspective and with consideration of cost-
effectiveness, a conservative approach as in best
medical treatment is warranted.
Generally, total costs of treatment (V36,600 vs.
28,700 per patient over 2 years) were high. Costs of
in-hospital-stay and institutional rehabilitation con-
stituted the predominant part of the total costs of
medical care in CLI. Compared with the average age-
and sex-specific health care expenditure per Dutch
person (V5150 annually, V10,300 over 2 years), costs
are three times higher.
The TransAtlantic Inter-Society Consensus (TASC)
document expressed concern about the lack of good
quality data concerning cost-effectiveness of inter-
ventions in peripheral arterial occlusive disease
(PAOD). Nonetheless, several groups reported data
on (hospital) costs of CLI, revascularisation pro-
cedures and amputation.24–26,34–40 On average, long-
term costs following revascularisation for CLI were
estimated at $23,000–28,000. Hospital costs were
approximately $11,000 for successfulEur J Vasc Endovasc Surg Vol 31, May 2006
Table 2. Unit cost of relevant cost items in critical limb ischemia [Euro]
Direct medical cost items Cost components Unit cost [Euro]
University
hospital
General
hospital
In hospital
Inpatient care (per day) Time/attendance registration, department-based
cost registration
General ward 181 151
Intensive care unit 1150 1027
Operative procedures Time/attendance registration, department-based
cost registration
Amputation (toe) 266 117
(Forefoot) 430 235
(Foot) 554 382
(Below-knee) 667 406
(Above-knee) 695 554
SCS-implantation Time/attendance registration, SCS-implant,
department based cost registration
7823 7760
SCS-complication treatment 715 685
Outpatient clinic (per visit) Department based cost registrations 32 30
Routine tests on general ward (per day) Registration in patient sample (nZ18) 17
Medication use on general ward (per day) Department of vascular surgery 10
Rehabilitation
ConsultationCfollow-up (per x days) Estimates based on reimbursement fees 55Cx!10
Day-programme (per day) Estimates based on reimbursement fees 59
Outside hospital
Rehabilitation centre (per day) National Hospital Institute report 227
Nursing home (per day) Ministry of Health report 101
Home for the elderly (per day) Ministry of Health report 48
Medical supplies, e.g.
Crutches (per pair) Public Health Service prices 41
Standard wheel-chair Public Health Service prices 559
Below-knee prosthesis Manufacturer’s prices 1682
Medication use (per individual patient) Standard dose prices of recorded medicine Spec.
General practitioner (per visit) Reimbursement fee 34
Professional care, e.g.
Day-care (per day) Ministry of Health report 55
Domestic social service (per hour) Institute Medical Technology Assessment,
Rotterdam
16
Nurse (per hour) Ministry of Health report 34
Direct non-medical cost items
Travel expenses (per travelled kilometre) Kilometre price (car/public transportation/taxi) 0.20/0.09/0.60
Time lost working See text –
Out-of-pocket expenses Social Services (for the handicapped) 150–340
Indirect non-medical cost items
Non-professional help (per hour) Institute Medical Technology Assessment,
Rotterdam
5.5
H. M. Klomp et al.504revascularisation ($9000–11,000 for angioplasty,
$11,000–15,000 for surgery), compared with $22,000
for failed revascularisation. Each additional pro-
cedure increased the cost by $9000. The costs for
revascularisation and primary amputation were
similar when the costs of a prosthesis and
rehabilitative therapy were included. Primary ampu-
tation costs were reported between $17,000 and
21,000, secondary amputations lead to higher cost
($25,000–28,000).
For all important cost items, we estimated real
costs rather than reimbursement fees or charges. Cost
of in-hospital-stay was assessed in detail, since this
was the main element of total costs of treatment.Eur J Vasc Endovasc Surg Vol 31, May 2006Over 80% of in-hospital days were directly related to
CLI. Meticulous cost evaluation was also performed
for operative procedures, but cost of amputation
proved to be relatively unimportant compared to
SCS-implantation. Although some differences were
observed between the treatment groups as to the
rehabilitation facility (rehabilitation clinic or nursing
home) and the type of home care (home for the
elderly or domestic professional care), combined
costs for rehabilitation and home care were compar-
able. Due to the Dutch health care structure, costs are
somewhat higher in university hospitals than in
general hospitals. This does have some influence on
(total) costs in university hospitals (w10% higher),
Table 3. Days spent in hospital, rehabilitation centre or nursing
home in both treatment groups within 2 years after randomisation
Type of institution Cumulative days (2 years)
SCS (nZ60) Standard (nZ60)
In-hospital-stay
Directly related to CLI 2523 2544
Related to CLI 480 537
Unrelated to CLI 186 39
Rehabilitation centre 623 1047
Nursing home 1607 1040
Cost-effectiveness of SCS in Critical Limb Ischaemia 505however, due to stratified randomisation this does
not modify either cost comparisons between two
groups or costs components (%).
A common problem when using clinical trials for
any kind of cost assessment arises from the fact that
the clinical protocol mandates more visits, consul-
tations and examinations than otherwise used in
clinical practice.41 For a treatment in a research setting,
there will generally be more costs, compared to daily
practice. In this study, costs from protocol-driven
medical care may have arisen in the outpatient costs.
However, these were very limited and comprised less
than 3% of the total costs.
With hindsight, all individual randomised studies
on SCS for peripheral vascular disease, including the
one described in this article, were underpowered.
This was mainly due to the assumption that limb
survival in the control group would be much lower
(based on the literature data 20–40% at 1 year) and
that 20–30% improvement in limb survival would be
attained readily. However, the conservative (i.e. best
medical) treatment groups showed much better
outcomes.
A recent ‘systematic review’18,19 included six
studies, with patient numbers varying from 27 toTable 4. Cumulative mean cost per patient (Euro)
Time
(months)
Cost
(Euro)
Hospital Oper-
ations
Rehab Eld. ho
1 SCS 2.694 7.808 17 185
3 5.425 8.041 548 545
6 7.126 8.083 3.081 1.240
12 8.586 8.131 4.740 2.547
18 10.290 8.376 5.869 3.339
24 11.799 8.376 6.759 3.803
1 Standard 1.695 72 54 142
3 3.982 189 1.095 308
6 6.740 278 3.839 536
12 10.990 417 6.253 814
18 11.740 417 7.323 1.226
24 12.342 417 7.484 1.341
Cost components are shown as: hospital, cost of hospital admission in
amputations; rehabilitation, cost of admission to rehabilitation center o
elderly; homecare, cost of professional day care, general practitioner, di
medication use and medical supplies; outpatient, consultation, cost of
non-medical cost, cost of non-professional help, travel expenses, out-o120 patients. The most important problem of this
review was the inclusion of a ‘controlled’ (non-
randomised) study by Amann.17 In this study,
patients were classified according to transcutaneous
pO2 measurements and did or did not receive SCS
treatment based on this TcpO2 classification and trial
stimulation. Over 30% of the patients in the ‘control’
(conservative) arm underwent amputation within 2
weeks, illustrating intense selection bias. This study
should be seen as a prognostic study using TcpO2
measurements, rather than an adequate comparison
of treatments. Remarkably, the limb survival curves
were quite comparable after the initial period. In
addition, amputation data input was incorrect for
two studies,22,42 the use of data from a subgroup of
the smallest study43 is artificial, and for at least three
studies42–44 concealment of treatment allocation was
dubious. The value of any meta-analysis is totally
dependent on lack of bias in its component studies.45
Hence, in a meta-analysis of clinical trials, it is
important to restrict inclusion to randomised trials,
ideally with adequate concealment of treatment
allocation, intention-to-treat analysis and objective
outcome assessment. Fig. 3 shows a meta-analysis
performed with amputation data input of all (nZ5)
randomised studies at 18 months, generating a risk
difference for amputation of K0.07 [95% CI: K0.17 to
C0.03] pZ0.15 with corresponding relative risk
estimate of 0.80 [95% CI: 0.60–1.06]. As regards
these estimates, one should make allowance for
dubious concealment of treatment allocation in
three studies, which usually is associated with
exaggeration of treatment effects by 40%.46,47
In conclusion, practical benefit from SCS as
compared to best medical treatment alone in terms ofme Home-
care
Medi-
cation
Outpati-
ent
Non-med Total
171 55 123 110 11.163
490 253 287 260 15.849
816 608 420 402 21.776
1.549 1.092 607 599 27.851
1.916 1.362 772 813 32.736
2.316 1.483 995 1.031 36.563
306 112 98 102 2.581
953 439 225 215 7.405
1.639 1.117 351 324 14.824
2.559 1.806 587 470 24.167
3.197 1.958 677 555 27.093
3.695 2.010 749 627 28.665
-hospital stay; operations, cost of the SCS-device and implantation,
r nursing home; elderly home, cost of admission to home for the
strict nurse, professional domestic help; medication, supplies, cost of
outpatient visits, consultation for rehabilitation, prosthesis (fitting);
f-pocket expenses.
Eur J Vasc Endovasc Surg Vol 31, May 2006
Fig. 3. Meta-analysis of randomised studies on SCS in critical limb ischaemia.
Fig. 2. Components of cumulative mean cost per patient over 2 year.
H. M. Klomp et al.506(limb) survival has not been established. If SCS is
beneficial, the magnitude of the effect is small. The
NNT to save one limb would be approximately 13,
resulting in costs of around V100,000 per limb saved.
In view of the high costs associated with limb-
threatening ischaemia and its treatment, initial high
costs of future therapy developments seem acceptable,
particularly if substantial benefit is expected and leads
to a decrease of in-hospital days and rehabilitative
institutionalisation.Acknowledgements
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